Biogen Inc. (BIIB)
| Market Cap | 33.89B |
| Revenue (ttm) | 9.99B |
| Net Income (ttm) | 1.46B |
| Shares Out | 144.90M |
| EPS (ttm) | 10.07 |
| PE Ratio | 23.75 |
| Forward PE | 16.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,221,270 |
| Open | 237.77 |
| Previous Close | 233.87 |
| Day's Range | 235.74 - 239.93 |
| 52-Week Range | 220.86 - 319.76 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 326.52 (+36.55%) |
| Earnings Date | Nov 8, 2023 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosi... [Read more]
Financial Performance
In 2022, Biogen's revenue was $10.17 billion, a decrease of -7.36% compared to the previous year's $10.98 billion. Earnings were $3.05 billion, an increase of 95.80%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for BIIB stock is "Strong Buy." The 12-month stock price forecast is $326.52, which is an increase of 36.55% from the latest price.
News
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
Biogen Inc. BIIB, -1.21% on Wednesday reported third quarter results that topped analyst estimates, even as it navigates a complex launch of its new Alzheimer's treatment Leqembi.
Biogen cuts annual profit forecast on persistent higher costs
Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on rising costs related to the recent acquisition of rare disease drugmaker Reata Pharmaceuticals and the launch of i...
Biogen Earnings Are Soon. What to Watch.
Wall Street will likely be more interested in updates on future developments, rather than the latest quarter's numbers.
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Biogen and Sage Therapeutics' oral pill to treat postpartum depression (PPD) in adults is expected to cost U.S. wholesalers $15,900 for a full 14-day treatment, Sage Therapeutics said on Tuesday.
Biogen Appoints Monish Patolawala to its Board of Directors
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”...
Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger
Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug.
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug.
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV
New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy...
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a fi...
RBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030
CNBC's Angelica Peebles reports on opportunities in the pharmaceutical sector.
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upcoming Clinical Trials on Alzheimer's Disease (CTAD...
Final Trades: BIIB, XRT, TSLA & GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trades: WST, BIIB, SPY & MDT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Biogen gets FDA approval for biotech treatment similar to Roche's Actemra
Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, or ...
FDA Approves Biogen's TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formula...
Biogen Completes Acquisition of Reata Pharmaceuticals
CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeut...
Are Gene Therapy Stocks The Market's Next Big Winners?
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD...
Japan approves Alzheimer treatment Leqembi by Eisai and Biogen
Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen.
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massac...
Call of the day: The health care trade
CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.
Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management
MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., announced that it plans to conduct an observational, real-world study with Biogen (Nasdaq: BIIB) as the sponsor.
Biogen names Dr. Jane Grogan head of research effective Oct. 2
Biogen Inc. BIIB said Wednesday it has appointed Dr. Jane Grogan as head of research, effective Oct. 2. Grogan was most recently chief scientific officer at Graphite Bio, a cell and gene editing compa...
Biogen Appoints Jane Grogan as Head of Research
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023....